#Obesity medicine
Chronic weight management as a clinical specialty.
GLP-1 Patient Experiences in Jeddah
A survey in three Jeddah hospitals recorded patient concerns about GLP-1 medicines, but its cross-sectional design cannot establish causation.
Semaglutide ASCVD cost model
A US veteran model found lifetime semaglutide added 1.31 QALYs but cost $118,996 per QALY at an assumed $14,000 annual price.
Facial nodules and compounded tirzepatide
One case linked facial nodules to compounded tirzepatide, but missing biopsy and cultures leave inflammation, infection and product factors unresolved.
GLP-1 drugs before surgery: what changed
A 2026 surgical review supports risk-based planning for semaglutide and tirzepatide, but it reports no new trial or aspiration rate.
GLP-1 Mental Health Data in Teens
A small chart review found no short-term increase in suicidality screens among adolescents with obesity using liraglutide or semaglutide.
Incretin weight loss in type 1 diabetes
A 70-person study linked liraglutide, semaglutide, or tirzepatide treatment with fat loss, modest lean loss, and stable total-body bone density.
Tirzepatide and Work: Survey Findings
A survey of 518 US employees starting tirzepatide found strong support for obesity-drug coverage, but it did not measure treatment effects.
Foundayo's $98 million launch quarter
Lilly reported $98 million in Q2 revenue for oral GLP-1 Foundayo. The filing shows an early launch, not proof that the medicine disappointed.
GLP-1 Drugs and Skin Disease Evidence
A 2026 review finds the strongest GLP-1 skin evidence in psoriasis, while most other dermatology uses remain observational.
Do GLP-1 Drugs Affect Muscle and Bone?
A 2026 meta-analysis found a low-certainty lean-mass signal with GLP-1 drugs, but no adjusted effect on bone or joint outcomes.
Semaglutide in type 1 diabetes: ADJUST-T1D
ADJUST-T1D found better glucose-and-weight outcomes with semaglutide in selected adults, but it did not test long-term cardiovascular benefit.
Tirzepatide anhedonia: three case reports
Three patients reported improved motivation after tirzepatide dose reduction, but the uncontrolled case series cannot establish frequency or causation.